Spinal Cord Stimulation: Candidates, Conditions & Trial
Interventional Pain Management Physician, Chief of the Division of Pain Medicine at Good Samaritan University Hospital, and Founder of SpinePain Solutions. Dr. Sharma completed fellowship training in pain medicine at Johns Hopkins and has practiced interventional pain medicine since 2004.
Spinal cord stimulation (SCS) is an implanted neuromodulation treatment for selected chronic pain conditions. Thin leads positioned in the epidural space deliver programmed electrical pulses that change how pain signals are processed. SCS does not remove a disc herniation, open a narrowed spinal canal or cure neuropathy. Its purpose is to reduce the impact of pain enough to improve meaningful activities and quality of life.
A strong spinal cord stimulator candidate usually has chronic, function-limiting neuropathic or appropriately selected refractory back or limb pain, a reasonably established diagnosis, no untreated problem that is better corrected surgically, and an inadequate response to suitable nonimplant treatment. The patient must also be able to complete a temporary trial and participate in programming and long-term device care.
SCS is most established for selected chronic neuropathic pain patterns, including persistent neuropathic back or leg pain after spine surgery and medically refractory painful diabetic neuropathy. It may also help carefully selected patients with chronic back pain without previous surgery, radicular pain, complex regional pain syndrome (CRPS) or causalgia. A diagnosis alone does not guarantee success: the pain mechanism, anatomy, treatment history, goals and trial response all matter.
What Is Spinal Cord Stimulation?
A spinal cord stimulation system usually includes one or more thin leads and an implanted pulse generator. The leads are placed in the epidural space, outside the spinal cord itself. The generator sends programmable electrical pulses through contacts on the leads. A handheld controller or app may allow the patient to turn therapy on or off, select approved programs and adjust settings within prescribed limits.
SCS is often described as “blocking” pain signals, but that explanation is too simple. Depending on the waveform, location and pain condition, stimulation may influence spinal pain transmission, inhibitory neural circuits, sensory processing and signaling within the wider nervous system. The exact biological effects are not fully understood and are not identical for every type of stimulation.
Will I Feel Tingling?
Some traditional paresthesia-based programs replace part of the painful area with a comfortable tingling sensation. Other approaches, including high-frequency, burst and additional sub-perception programs, may be used without noticeable tingling. Feeling paresthesia is therefore not required for every modern SCS system.
The appropriate waveform and device cannot be selected by marketing claims alone. Pain pattern, prior treatment, MRI needs, charging preferences, dexterity, body size, programming response and long-term support all deserve consideration.
What Conditions Can Spinal Cord Stimulation Treat?
The conditions treated with spinal cord stimulation are not equally supported by evidence, and patients with the same diagnosis can respond differently. SCS tends to fit pain with a neuropathic component better than pain arising primarily from an untreated mechanical or surgically correctable problem.
| Condition or pain pattern | How SCS should be considered |
|---|---|
| Persistent neuropathic pain after lumbar surgery | An established application, especially for neuropathic leg pain. Evaluation should first determine whether recurrent compression, instability or another problem has a better surgical solution. |
| Painful diabetic neuropathy | Modern randomized evidence supports SCS for selected patients with medically refractory painful lower-extremity diabetic neuropathy. It is not a treatment for painless numbness or every form of neuropathy. |
| Chronic refractory back pain without previous surgery | May be considered in carefully selected patients without a correctable surgical lesion. Device-specific trials report benefit, while placebo-controlled and long-term evidence remains debated. |
| Chronic radicular or neuropathic limb pain | May fit when symptoms are chronic and anatomically coherent and are not better treated with decompression or another targeted therapy. |
| CRPS or causalgia | Neuromodulation may help selected patients. Dorsal root ganglion stimulation deserves comparison when lower-extremity pain is focal, such as pain centered in a foot, knee or groin. |
| Chronic neck or arm neuropathic pain | A possible selected application, although the evidence base is less mature than for common lumbar indications and cervical implantation requires its own anatomical risk assessment. |
| Other peripheral neuropathies | Evidence and insurance coverage vary by cause and system. A painful focal neuropathy may sometimes be better suited to peripheral nerve stimulation. |
| Predominantly mechanical facet, sacroiliac or instability pain | SCS is generally not the first implant strategy. Diagnosis-specific treatment, rehabilitation, radiofrequency ablation or stabilization may be more appropriate. |
| Active nerve compression with progressive neurological loss | Urgent structural evaluation takes priority. SCS does not decompress the spinal canal or reverse a progressive deficit. |
| Diffuse pain without a clear treatment target | Benefit is less predictable. SCS is not routine treatment for every form of generalized or nociplastic pain. |
Persistent Pain After Spine Surgery
SCS has a long-standing role for carefully selected patients with persistent neuropathic back or leg pain after lumbar surgery, sometimes called failed back surgery syndrome or persistent spinal pain syndrome. The PROCESS randomized trial found better outcomes with SCS plus conventional medical management than conventional medical management alone in its selected population with predominant neuropathic leg pain.
This evidence should not be generalized to every patient with pain after an operation. Updated imaging may be needed to look for recurrent disc herniation, persistent stenosis, pseudarthrosis, instability, infection or another correctable source. Learn more about persistent pain after spine surgery.
Painful Diabetic Neuropathy
The SENZA-PDN randomized trial and its 24-month follow-up reported substantial group-level improvements with 10-kHz SCS in selected patients with medically refractory painful diabetic neuropathy. These results apply to the trialâs screened population; they do not mean that SCS restores normal sensation, reverses diabetes or treats every peripheral neuropathy.
Diabetes management, foot protection, medication review and evaluation for other causes of neuropathy remain important even if SCS reduces pain.
Nonsurgical Refractory Back Pain
Previous spine surgery is not required for every SCS candidate. Randomized device-specific studies have reported benefit in carefully selected patients with chronic refractory low back pain who had not undergone surgery and did not have a surgically correctable lesion. However, a 2023 Cochrane review found no clinically important benefit over placebo at six months in the qualifying placebo-controlled study and emphasized the absence of long-term placebo-controlled evidence.
The evidence is therefore not settled for all forms of nonsurgical back pain. Before SCS, the evaluation should define whether pain is neuropathic, vertebrogenic, disc-related, facet-mediated, sacroiliac, instability-related or mixed. A broad label such as âchronic back painâ is not enough.
CRPS, Causalgia and Other Neuropathic Pain
SCS may help selected people with CRPS or causalgia. When pain is focal and concentrated in part of a lower extremity, dorsal root ganglion stimulation may offer more targeted coverage. In the ACCURATE randomized comparative trial, DRG stimulation produced higher treatment success than traditional SCS in the selected study population with lower-extremity CRPS or causalgia.
For pain localized to a named peripheral nerve, peripheral nerve stimulation may be considered instead. The best neuromodulation target depends on pain distribution, diagnosis, anatomy and trial response.
Who Is a Good Candidate for a Spinal Cord Stimulator?
Candidacy is not determined by how many treatments have âfailedâ or by a diagnosis name alone. The pain mechanism must plausibly respond to neuromodulation, the expected benefit must justify the implant burden and risks, and the patient must be able to use and maintain the system.
| Findings that support consideration | Findings that need treatment or evaluation first |
|---|---|
| Chronic, function-limiting neuropathic or appropriately selected mixed pain | Acute pain that is expected to improve or pain without a reasonably established cause |
| Symptoms, examination and diagnosis that form a coherent pattern | A major competing pain generator or symptoms that do not match the proposed target |
| Inadequate improvement with reasonable diagnosis-specific nonimplant treatment | An appropriate lower-risk treatment has not yet been attempted |
| No clearly better surgical solution | Progressive weakness, untreated compression, instability or another correctable lesion |
| Realistic goals involving walking, sleep, work, self-care or medication burden | Expectation of a cure, guaranteed relief or complete elimination of pain |
| Ability to operate the controller, recharge if needed and attend programming visits | Cognitive, logistical or adherence barriers that cannot be safely addressed |
| Acceptable infection, bleeding and anesthesia risk | Active infection, uncontrolled bleeding risk or another unacceptable medical risk |
| Psychosocial screening and informed expectations | Active psychosis, ongoing untreated substance-use disorder or uncontrolled factors that materially prevent safe care |
| Meaningful, multidimensional improvement during the trial | An inconclusive trial or inadequate improvement in pain, function or quality of life |
Evaluation Before SCS
The evaluation may include a detailed pain history, neurological and musculoskeletal examination, review of prior procedures and medications, and updated imaging when indicated. The physician should determine whether pain is mainly neuropathic, nociceptive, mechanical, nociplastic or mixed and whether another treatment has a more direct target.
Psychological or psychosocial assessment does not mean the pain is imaginary. It helps identify depression, anxiety, untreated substance-use problems, cognitive concerns, expectations, coping patterns and practical barriers that may affect safety, trial interpretation and long-term device use. The 2023 multisociety patient-selection consensus recommends validated psychosocial screening that includes depression.
Age, body mass index, smoking, opioid use or a cardiac implant should not automatically be converted into a single universal exclusion. Each may alter risk, expected outcome, technical planning or insurance requirements and should be evaluated individually.
When SCS May Not Be the Right Treatment
SCS is generally inappropriate when pain is acute and likely to resolve, the pain generator remains unclear, the symptoms arise primarily from an untreated mechanical problem, or a correctable lesion requires decompression or stabilization. It should also be delayed when there is active infection, uncontrolled bleeding risk or another medical condition that makes implantation unsafe.
New or progressive weakness, loss of bowel or bladder control, saddle-region numbness, rapidly worsening balance or severe pain with fever may indicate compression, infection or another urgent problem. SCS does not replace emergency evaluation or surgical treatment when a time-sensitive structural cause is present.
What Are the Alternatives to Spinal Cord Stimulation?
The appropriate alternative depends on the diagnosis and pain mechanism. Options may include:
- Medication optimization, physical rehabilitation and home exercise
- Cognitive-behavioral or interdisciplinary pain treatment
- Epidural injection or selective nerve-root injection for selected radicular pain
- Radiofrequency ablation for confirmed facet-joint or sacroiliac-joint pain
- Spinal decompression or stabilization for a correctable structural lesion
- DRG stimulation for selected focal pain patterns
- Peripheral nerve stimulation for pain localized to a named peripheral nerve
- Intrathecal drug-delivery therapy in carefully selected circumstances
- Continued nonimplant treatment when the expected SCS benefit does not justify device burden or risk
SCS Versus DRG and Peripheral Nerve Stimulation
| Approach | Typical target | Decision considerations |
|---|---|---|
| Spinal cord stimulation | Broader back, leg, neck or arm pain patterns | Most established across several chronic neuropathic conditions; coverage and response depend on diagnosis and device. |
| DRG stimulation | Focal, anatomically concentrated pain such as selected lower-extremity CRPS or causalgia | May provide targeted coverage in areas that can be difficult to capture with conventional SCS. |
| Peripheral nerve stimulation | Pain associated with a specific peripheral nerve | Places therapy closer to the named nerve and may avoid a broader spinal target when pain is localized. |
None of these approaches is universally superior. A more targeted system may fit focal pain, while a broader pain distribution may favor SCS. MRI compatibility, recharge requirements, implant location, coverage policy and the clinicianâs experience also influence the choice.
What Happens During a Spinal Cord Stimulator Trial?
A temporary trial allows the patient and physician to test SCS before committing to a permanent implant. The exact technique, duration and coverage requirements vary, but a typical percutaneous trial includes:
- Preparation: medications, infection risk, allergies and the treatment plan are reviewed. Blood-thinner instructions must be individualized.
- Lead placement: one or more temporary leads are advanced through needles into the epidural space using fluoroscopic X-ray guidance.
- Programming: the leads are connected to an external generator and programmed for the patientâs pain pattern.
- Home assessment: the patient tracks pain, walking, sleep, daily activity, medication use and overall satisfaction during the trial period.
- Lead removal and review: temporary leads are removed, the response is reviewed and permanent implantation is considered only if the overall benefit is meaningful.
Activity is restricted during the trial to reduce lead displacement and infection risk. Patients should keep dressings dry, avoid pulling on the external components and follow the specific bending, lifting and twisting instructions provided by the treating team.
What Counts as a Successful Trial?
Many studies and insurers use at least 50 percent pain reduction as one benchmark. Clinical success, however, should not be reduced to a single percentage. A meaningful trial may also improve walking, sleep, self-care, work tolerance, medication use or the ability to complete a personally important activity.
Goals should be chosen before the trial so the result is not judged from memory alone. A successful trial supports permanent implantation but does not guarantee that the permanent system will reproduce the same degree or duration of benefit.
Permanent Implantation and Recovery
A permanent system includes implanted leads and a pulse generator placed in a subcutaneous pocket, commonly in the flank, buttock or abdominal region. Leads may be placed percutaneously, while paddle leads require a surgical approach. The technique, anesthesia and discharge plan depend on the system, anatomy, health status and clinical setting.
Permanent implantation involves more healing than the temporary trial because of the generator pocket and incisions. Incisional and pocket soreness can initially be more noticeable than the underlying pain relief. Walking is usually encouraged, but bending, lifting, twisting and strenuous activity are limited while the incisions heal and the leads stabilize. Restrictions should be individualized rather than assumed to follow one universal timeline.
Patients should receive instructions about wound care, showering, driving, work, sleep position and warning signs. Programming adjustments may be needed over several visits. The first program is not always the best long-term program.
Living With an Implanted System
- Charging: rechargeable generators require regular charging. Nonrechargeable generators eventually require replacement when the battery is depleted.
- Programming: pain patterns and programming needs can change. Follow-up and reprogramming are part of long-term care.
- MRI: eligibility depends on the complete implanted system and its specific MRI-conditional requirements. Abandoned or mismatched components may change access.
- Procedures and surgery: clinicians should be told about the implant before MRI, surgery, electrocautery, cardiac procedures or other treatments that could interact with the system.
- Identification: patients should keep their device identification card available, especially during travel and medical care.
- Future operations: generator replacement, lead revision or explantation may become necessary.
Pacemakers and Implantable Defibrillators
A pacemaker or implantable cardioverter-defibrillator is not automatically an absolute exclusion. A published review of documented SCS and cardiac-device interactions found interference to be rare, while also emphasizing the small and variable evidence base and the absence of universal guidelines.
Feasibility should be determined case by case. Coordination may include the pain physician, cardiologist or electrophysiologist and device manufacturers, with interrogation and testing during the trial, implantation and follow-up. Device-specific instructions take priority.
What Does the Evidence Show?
The SCS literature includes randomized trials, device-specific studies, observational cohorts, consensus statements and systematic reviews. Results should be interpreted by diagnosis, comparator, waveform, follow-up duration and study sponsorship rather than combined into one universal success rate.
Where Evidence Is More Established
- Persistent neuropathic pain after spine surgery: randomized evidence supports SCS in selected patients, particularly those with predominant neuropathic leg pain and no better surgical solution.
- Painful diabetic neuropathy: modern randomized evidence supports 10-kHz SCS in a selected medically refractory population, with follow-up reported through 24 months.
- CRPS and causalgia: neuromodulation can be considered, and randomized comparative evidence supports discussing DRG stimulation for selected focal lower-extremity pain.
Where Important Uncertainty Remains
- Evidence for nonsurgical refractory back pain varies by device and study design, and placebo-controlled long-term evidence remains limited.
- Newer waveforms and emerging indications do not all have equally mature long-term evidence.
- Industry support and investigator relationships are common in device research and should be considered when interpreting large effect estimates.
- A trial is useful but imperfect; it cannot guarantee identical permanent-implant results.
- Benefit may diminish with time, disease progression, a new pain generator, lead movement or other factors.
A 2025 systematic appraisal of SCS guidelines and consensus statements found strong emphasis on patient selection and perioperative management but continuing gaps in long-term data for newer waveforms, emerging indications, psychological evaluation and holistic outcomes.
SCS may reduce pain and improve function without making the pain score zero. Some patients continue medications, rehabilitation or other treatment. Reprogramming, revision or removal may eventually be needed.
Risks and Long-Term Device Management
Spinal cord stimulation is reversible in the sense that the system can usually be removed, but implantation and explantation are still invasive procedures. Potential risks include:
- Infection involving the skin, pocket, leads or deeper tissues
- Bleeding, including epidural hematoma
- Dural puncture, cerebrospinal fluid leak and spinal headache
- Nerve or spinal cord injury, weakness or paralysis
- Lead migration, fracture, disconnection or unwanted stimulation
- Generator-pocket pain, wound problems or hardware prominence
- Allergic or inflammatory reaction to implanted materials
- Battery, controller, charging or other hardware failure
- Difficulty achieving useful programming coverage
- Persistent pain, loss of benefit or development of a different pain generator
- Need for reprogramming, revision, generator replacement or explantation
- Medication, sedation or anesthesia complications
Lead migration is among the most frequently discussed hardware complications, but complication estimates vary with device type, implant technique, follow-up duration and how events are defined. The 2024 comprehensive complications review provides a broader discussion of biological, hardware and therapy-related problems.
New weakness, loss of bowel or bladder control, fever, wound drainage, severe positional headache, rapidly increasing pocket swelling, chest pain, shortness of breath or sudden loss of therapy should be reported promptly. Emergency symptoms require urgent medical evaluation.
Questions to Ask Before an SCS Trial
- What is the most likely source and mechanism of my pain?
- Does my imaging show a problem that should be corrected before SCS?
- Which activities will we use to judge whether my trial is successful?
- What improvement does my insurance require?
- Which system and waveform are being considered, and why?
- Will the system require charging?
- What MRI access would I have with the complete system?
- Where would the generator be placed?
- What are my individualized infection, bleeding and neurological risks?
- What restrictions will apply during the trial and after implantation?
- Who will provide programming and device support over time?
- What are the alternatives if the trial is inconclusive or unsuccessful?
Spinal Cord Stimulation Evaluation on Long Island
A careful SCS evaluation should do more than confirm that pain has lasted a long time. It should identify the pain mechanism, review imaging and prior care, exclude a better structural treatment, establish measurable goals and explain the long-term responsibilities of an implanted device.
At Amit Sharma MD, the evaluation is individualized to the diagnosis, pain distribution, medical risk, functional limitations and treatment goals. The recommendation may be an SCS trial, a different neuromodulation target, further diagnostic work, a nonimplant treatment or surgical evaluation when the anatomy requires it.
Dr. Amit Sharma & our minimally invasive pain & spine team.
Spinal Cord Stimulation FAQs
What is spinal cord stimulation?
Spinal cord stimulation is an implanted neuromodulation therapy for selected chronic pain conditions. Thin leads placed in the epidural space deliver programmed electrical pulses that change how pain signals are processed. The treatment manages pain; it does not repair a disc, decompress a nerve or cure the underlying condition.
Who is a good candidate for a spinal cord stimulator?
A good candidate generally has chronic, function-limiting neuropathic or appropriately selected refractory back or limb pain that has not improved adequately with other suitable treatments. The diagnosis should be established, surgically correctable causes should be excluded, medical and psychosocial risks should be assessed, and the patient should understand the responsibilities and limitations of an implanted system. Permanent implantation is usually considered only after a trial demonstrates meaningful benefit.
What conditions respond best to spinal cord stimulation?
Spinal cord stimulation has its most established role in selected chronic neuropathic pain conditions, including persistent neuropathic back or leg pain after spine surgery and medically refractory painful diabetic neuropathy. It may also help carefully selected patients with nonsurgical refractory back pain, chronic radicular pain, complex regional pain syndrome or causalgia. The diagnosis alone does not predict success; pain mechanism, anatomy, previous treatment, functional goals and the trial response all matter.
Do I need to have had spine surgery before spinal cord stimulation?
No. Previous spine surgery is not required in every case. Spinal cord stimulation may be considered for selected patients who have not had surgery when pain is chronic and refractory and evaluation does not identify a surgically correctable cause. Evidence and insurance coverage vary by diagnosis, device and clinical circumstances.
What happens during a spinal cord stimulator trial?
During a typical trial, temporary leads are placed through needles into the epidural space using X-ray guidance and connected to an external generator. The patient uses the system at home for a limited period while tracking pain, function, sleep, medication use and satisfaction. Trial details and activity restrictions vary.
What counts as a successful spinal cord stimulator trial?
Many studies and insurers use at least 50 percent pain reduction as one benchmark, but trial success should not be judged by one number alone. Meaningful improvement in walking, sleep, daily activity, medication use and satisfaction may also matter. Coverage requirements and clinical goals should be reviewed before the trial.
Does a successful trial guarantee that the permanent implant will work?
No. A successful trial increases confidence that spinal cord stimulation may help, but it cannot guarantee identical or permanent relief after implantation. Lead position, healing, programming, activity, disease progression and changes in the pain generator can affect the long-term response.
Will I feel tingling from a spinal cord stimulator?
It depends on the system and programming. Traditional paresthesia-based stimulation may create a comfortable tingling sensation in the painful area. High-frequency, burst and other sub-perception programs may provide therapy without noticeable tingling.
Can I have a spinal cord stimulator if I have a pacemaker or defibrillator?
A pacemaker or implantable defibrillator is not automatically an absolute exclusion, but compatibility must be evaluated individually. The pain physician, cardiologist or electrophysiologist and device representatives may need to coordinate testing, programming and follow-up for both systems.
Can I have an MRI with a spinal cord stimulator?
MRI access depends on the complete implanted system, including the generator, leads, lead position and any abandoned components. Some systems are MRI conditional only under specific scanning requirements. The exact device information must be checked before any MRI.
How long is recovery after permanent spinal cord stimulator implantation?
Incisional and generator-pocket soreness commonly improve over days to weeks. Walking is usually encouraged, while bending, lifting, twisting and strenuous activity are restricted during early healing to reduce lead movement. The exact timeline depends on the implant technique, health status and physician instructions.
What are the main risks of spinal cord stimulation?
Risks include infection, bleeding, epidural hematoma, dural puncture and headache, neurological injury, lead migration or breakage, generator-pocket pain, uncomfortable stimulation, programming difficulty, battery or hardware failure, loss of benefit, revision and explantation. Serious neurological complications are uncommon but possible.
Selected References
- Shanthanna H, et al. Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain. Regional Anesthesia and Pain Medicine. 2023. Full text.
- Kumar K, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain after spine surgery: the PROCESS randomized trial. Pain. 2007. PubMed.
- Petersen EA, et al. Effect of high-frequency spinal cord stimulation on pain and neurological function in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurology. 2021. PubMed.
- Petersen EA, et al. Long-term efficacy of high-frequency spinal cord stimulation for painful diabetic neuropathy: 24-month results. Diabetes Research and Clinical Practice. 2023. PubMed.
- Kapural L, et al. Treatment of nonsurgical refractory back pain with high-frequency spinal cord stimulation: a randomized controlled trial. Journal of Neurosurgery: Spine. 2022. PubMed.
- Traeger AC, et al. Spinal cord stimulation for low back pain. Cochrane Database of Systematic Reviews. 2023. PubMed.
- Deer TR, et al. Dorsal root ganglion stimulation versus spinal cord stimulation for CRPS and causalgia: the ACCURATE randomized comparative trial. Pain. 2017. PubMed.
- Martens JM, et al. Use of spinal cord stimulators in patients with pacemakers or implantable cardiac defibrillators: a review of documented accounts of interference. Neuromodulation. 2023. PubMed.
- Koushik SS, et al. Complications of spinal cord stimulators: a comprehensive review article. Current Pain and Headache Reports. 2024. PubMed.
- Elliott T, et al. Spinal cord stimulation guidelines and consensus statements: systematic review and AGREE-II appraisal. Neuromodulation. 2025. PubMed.
